JPH0565491B2 - - Google Patents
Info
- Publication number
- JPH0565491B2 JPH0565491B2 JP63203016A JP20301688A JPH0565491B2 JP H0565491 B2 JPH0565491 B2 JP H0565491B2 JP 63203016 A JP63203016 A JP 63203016A JP 20301688 A JP20301688 A JP 20301688A JP H0565491 B2 JPH0565491 B2 JP H0565491B2
- Authority
- JP
- Japan
- Prior art keywords
- anticancer
- precipitate
- polysaccharide
- present
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001093 anti-cancer Effects 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000002244 precipitate Substances 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241001261506 Undaria pinnatifida Species 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 241001474374 Blennius Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 229930105110 Cyclosporin A Natural products 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229960001265 ciclosporin Drugs 0.000 description 5
- 229930182912 cyclosporin Natural products 0.000 description 5
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 1
- PLDLXZBHSVQZNN-CRKDRTNXSA-N (2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-chloro-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(Cl)O[C@H](CO)[C@@H](O)[C@H]1O PLDLXZBHSVQZNN-CRKDRTNXSA-N 0.000 description 1
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FNEHAOQZWPHONV-UHFFFAOYSA-N 9h-carbazole;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C3=CC=CC=C3NC2=C1 FNEHAOQZWPHONV-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960000834 vinyl ether Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63203016A JPH0253731A (ja) | 1988-08-15 | 1988-08-15 | 抗癌活性物質 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63203016A JPH0253731A (ja) | 1988-08-15 | 1988-08-15 | 抗癌活性物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0253731A JPH0253731A (ja) | 1990-02-22 |
| JPH0565491B2 true JPH0565491B2 (enrdf_load_stackoverflow) | 1993-09-17 |
Family
ID=16466949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63203016A Granted JPH0253731A (ja) | 1988-08-15 | 1988-08-15 | 抗癌活性物質 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0253731A (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3876271B1 (ja) * | 2006-03-03 | 2007-01-31 | 馬渡 祥二 | 免疫賦活剤 |
| JP6509618B2 (ja) * | 2015-04-16 | 2019-05-08 | 理研ビタミン株式会社 | サーチュイン遺伝子活性化剤 |
-
1988
- 1988-08-15 JP JP63203016A patent/JPH0253731A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0253731A (ja) | 1990-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6977059B2 (ja) | マンヌロン二酸の組成物 | |
| US5843452A (en) | Immunotherapy composition and method | |
| JPH08500589A (ja) | アストラガルス ポリサッカライド免疫調節剤 | |
| CA2468314C (en) | The use of water-soluble lamarin in the treatment of cancer | |
| JPS60214741A (ja) | 血糖降下剤 | |
| GB2082066A (en) | Neem bark extracts possessing antineoplastic activities | |
| JPH01157995A (ja) | 鎮痛−抗炎症活性を有するガングリオシドの内部エステル | |
| Shahriar et al. | Membrane stabilizing and thrombolytic activity of Withania somnifera root | |
| JPH0539305A (ja) | アストラガルス・メンブラナセウスから抽出した免疫 変調性多糖類及びこれらを含有する薬剤組成物 | |
| JP3294618B2 (ja) | ハルパゴフィツム プロカムベンスからのハルパゴシドに富む抽出物およびその製造方法 | |
| EP1789439B1 (en) | A purified arabinogalactan-protein (agp) composition | |
| JPH0565491B2 (enrdf_load_stackoverflow) | ||
| JP5133683B2 (ja) | サリコルニア・ブラキアタの抽出物の抗結核活性の亢進 | |
| US3151108A (en) | Kryptoescin and process of making same | |
| JP4424921B2 (ja) | 抗腫瘍剤 | |
| US3832343A (en) | Process for obtaining an extract of arnica montana | |
| US2870140A (en) | Therapeutic agents derived from rauwolfia serpentina | |
| JP3072321B2 (ja) | 抗ｈｉｖ活性物質およびその製造方法 | |
| JP4480204B2 (ja) | カワリハラタケの抗腫瘍性画分 | |
| JP2008050313A (ja) | 肝障害保護剤及びその分取法 | |
| JPH0267301A (ja) | 多糖類，その単離法および該多糖類を含む薬剤組成物 | |
| KR100338521B1 (ko) | 대식세포 활성화능을 갖는 식용식물 추출물 | |
| JPS63295512A (ja) | 制ガン剤 | |
| CN116606384B (zh) | 一种蒲黄均一多糖及其制备方法与抗肿瘤用途 | |
| CN113527175B (zh) | 一种巴旦木中氮甲基5-羟色胺的分离方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |